stockrowTG Therapeutics, Inc.
TGTX Healthcare Biotechnology
TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.
- Revenue
- +70.3%
- EPS
- −73.7%
- Free cash flow
- +427.1%
- Total debt
- +204.2%
Quarter to June 2026, against a year earlier
Follow TGTX
Alert me
TG Therapeutics, Inc. (TGTX) Current ratio
TG Therapeutics, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 4.3×, up 0.2× from fiscal 2025 (4.1×). Over the past ten years it has ranged from 1.8× (fiscal 2019) to 8.3× (fiscal 2015); the current reading is higher than 55% of that period. That is below the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 4.1× | (34.32%) |
| FY2024 | 6.2× | 5.53% |
| FY2023 | 5.9× | 87.12% |
| FY2022 | 3.2× | (37.51%) |
| FY2021 | 5.1× | (27.55%) |
| FY2020 | 7.0× | 295.60% |
| FY2019 | 1.8× | (13.17%) |
| FY2018 | 2.0× | (39.06%) |
| FY2017 | 3.3× | 10.76% |
| FY2016 | 3.0× | (63.48%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 4.3× | (26.55%) |
| Mar 2026 | 5.8× | 41.61% |
| Dec 2025 | 4.1× | 7.26% |
| Sep 2025 | 3.8× | (0.98%) |
| 42 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| SYRE Spyre Therapeutics, Inc. compare | 27.4× |
| PTGX Protagonist Therapeutics, Inc. compare | 21.7× |
| KRYS Krystal Biotech, Inc. compare | 7.9× |
| CAI Caris Life Sciences,�Inc. compare | 6.7× |
| IBRX ImmunityBio, Inc. compare | 5.7× |
| TGTX TG Therapeutics, Inc. | 4.3× |
| CYTK Cytokinetics, Incorporated compare | 3.4× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 3.1× |
| TWST Twist Bioscience Corporation compare | 2.7× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on TGTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement